Phosphatidylinositol is a basic cell-membrane building block central to how cells sense hormones and handle fats. As a supplement it is barely tested: one small company-funded study suggested better blood cholesterol and blood fats, but every other proposed benefit rests on lab reasoning. Safety looks good; digestive upset and soy allergy are the main concerns. (Full Review)
| Marker | Target | Why |
|---|---|---|
| HDL cholesterol | > 60 mg/dL | Primary reported target |
| Triglycerides | < 80 mg/dL | Secondary reported target |
| Apolipoprotein A-I | > 140 mg/dL | Main protein of HDL; rose in the human trial |
| Apolipoprotein B | < 80 mg/dL | Tracks atherogenic particle burden for context |
| Fasting insulin | < 6 µIU/mL | Screens the metabolic axis theorized to be affected |
| hs-CRP | < 1.0 mg/L | General inflammation and cardiometabolic context |
Cadence: Baseline, then re-check at 8–12 weeks, then every 6–12 months if continued